IAF BIOCHEM INTERNATIONAL TO BECOME BIOCHEM PHARMA INC. IN FEBRUARY 1992
IAF BIOCHEM INTERNATIONAL TO BECOME
BIOCHEM PHARMA INC. IN FEBRUARY 1992
LAVAL, Quebec, Jan. 16 /PRNewswire/ -- Dr. Francesco Bellini, president and chief executive officer of IAF BioChem International Inc. (NASDAQ: BCHXF), announced today that the company will change its name to BioChem Pharma Inc., beginning next month. This corporate name change, approved by the company's board of directors, must be ratified by shareholders at a special meeting scheduled for Feb. 19.
Bellini said the presence of the initials IAF in the company's name could leave the impression that there is an affiliation with the Institut Armand-Frappier (IAF), when in fact they are totally distinct and independent entities. The name change will not affect the excellent relations between the two organizations.
While retaining the advantages of the BioChem title, the company's new corporate name will also provide an indication of the evolution of the firm and its activities. BioChem is emerging as a totally integrated pharmaceutical company working in the industry's three main sectors: diagnostics, therapeutics and vaccines," Bellini explained.
Management also explained that the company logo, as well as its trading symbols -- BCH on the Montreal and Toronto stock exchanges and BCHXF on the NASDAQ exchange -- will remain unchanged.
IAF BioChem International Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases.
/CONTACT: Francesco Bellini, president and chief executive officer of IAF BioChem International, 514-681-1744, or Michele Roy or Luc Beauregard of National Public Relations, 514-843-7171, for IAF BioChem/
(BCHXF) CO: IAF Biochem International Inc.; BioChem Pharma Inc. ST: Quebec IN: MTC SU: SB-SM -- NY078 -- 0642 01/16/92 15:35 EST